Today, Analysts Set Evolent Health Inc. (EVH) Price Target at $27.80

Today, Analysts Set Evolent Health Inc. (EVH) Price Target at $27.80
Evolent Health Inc. (NYSE:EVH) has earned an average rating of “Buy” from the seven research firms that are currently covering the company. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $27.80.

Several equities research analysts have commented on EVH shares. Zacks Investment Research upgraded shares of Evolent Health from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Tuesday, October 11th. Jefferies Group set a $28.00 price target on shares of Evolent Health and gave the company a “buy” rating in a research note on Tuesday, October 4th. Leerink Swann restated a “buy” rating on shares of Evolent Health in a research note on Wednesday, October 5th. Canaccord Genuity set a $30.00 price target on shares of Evolent Health and gave the company a “buy” rating in a research note on Wednesday, September 28th. Finally, FBR & Co raised their price target on shares of Evolent Health from $24.00 to $26.00 and gave the company an “outperform” rating in a research note on Friday, August 5th.

Shares of Evolent Health (NYSE:EVH) opened at 21.05 on Wednesday. Evolent Health has a 1-year low of $8.14 and a 1-year high of $26.84. The stock’s market cap is $1.43 billion. The company has a 50-day moving average price of $21.18 and a 200-day moving average price of $20.78.

Evolent Health (NYSE:EVH) last issued its earnings results on Wednesday, November 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.02. Evolent Health had a negative net margin of 69.04% and a negative return on equity of 5.54%. The firm had revenue of $60.20 million for the quarter, compared to analysts’ expectations of $58.35 million. During the same quarter last year, the company posted ($0.16) earnings per share. Evolent Health’s revenue was up 39.0% on a year-over-year basis. On average, equities analysts expect that Evolent Health will post ($0.57) earnings per share for the current fiscal year.

In related news, President Seth Blackley sold 167,672 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $21.54, for a total transaction of $3,611,654.88. Following the transaction, the president now owns 869,848 shares in the company, valued at $18,736,525.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael D’amato acquired 10,000 shares of the stock in a transaction that occurred on Monday, November 14th. The shares were bought at an average price of $17.18 per share, for a total transaction of $171,800.00. Following the purchase, the director now directly owns 18,183 shares of the company’s stock, valued at $312,383.94. The disclosure for this purchase can be found here. Corporate insiders own 8.85% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of EVH. Capital World Investors raised its position in Evolent Health by 749.7% in the third quarter. Capital World Investors now owns 1,370,000 shares of the company’s stock worth $33,729,000 after buying an additional 1,208,762 shares in the last quarter. Peregrine Capital Management LLC bought a new position in Evolent Health during the third quarter worth approximately $26,294,000. JPMorgan Chase & Co. raised its position in Evolent Health by 60.1% in the third quarter. JPMorgan Chase & Co. now owns 2,142,800 shares of the company’s stock worth $52,755,000 after buying an additional 804,562 shares in the last quarter. Gilder Gagnon Howe & Co. LLC bought a new position in Evolent Health during the third quarter worth approximately $13,018,000. Finally, Citadel Advisors LLC bought a new position in Evolent Health during the third quarter worth approximately $6,340,000. Institutional investors and hedge funds own 37.14% of the company’s stock.

Related posts

Leave a Comment